| |
| |
|
| Insider
Information: |
Nea 14 Gp, Ltd |
| Relationship: |
10% Owner |
| City: |
Timonium |
| State: |
MD |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
92,551,179 |
|
|
Indirect Shares
|
9,425,523 |
|
|
| Direct
Value |
$95,736,137 |
|
|
|
Indirect Value
|
$21,147,239 |
|
|
| Total
Shares |
101,976,702 |
|
|
| Total
Value |
$116,883,375 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Loxo Oncology, Inc. |
LOXO |
10% Owner |
2013-08-06 |
1,789,420 |
2013-08-06 |
0 |
Premium* |
|
|
Avalo Therapeutics, Inc |
AVTX |
10% Owner |
2015-10-20 |
594,245 |
2015-10-20 |
0 |
Premium* |
|
|
Adaptimmune Therapeutics PLC |
ADAP |
10% Owner |
2018-09-07 |
82,978,668 |
|
0 |
Premium* |
|
|
Tracon Pharmaceuticals, Inc. |
TCON |
10% Owner |
2018-03-27 |
3,466,003 |
2018-03-27 |
3,466,003 |
Premium* |
|
|
Mersana Therapeutics, Inc. |
MRSN |
10% Owner |
2020-09-14 |
0 |
2020-09-14 |
5,959,520 |
Premium* |
|
|
Appian Corp |
APPN |
10% Owner |
2018-02-13 |
0 |
2018-02-13 |
0 |
Premium* |
|
|
Mulesoft, Inc |
MULE |
10% Owner |
2018-05-01 |
0 |
2018-05-01 |
0 |
Premium* |
|
|
Enliven Therapeutics Ord Shs |
ELVN |
10% Owner |
2021-12-23 |
3,722,843 |
2021-12-09 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
42 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ADAP |
Adaptimmune Therapeutics ... |
10% Owner |
– – • |
2016-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
59,269,000 |
|
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
10% Owner |
– – • |
2017-03-27 |
4 |
B |
$0.70 |
$9,009,000 |
D/D |
12,870,000 |
72,139,000 |
2.45 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
10% Owner |
– – • |
2018-03-21 |
4 |
B |
$1.81 |
$189,820 |
D/D |
104,844 |
72,243,844 |
2.45 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
10% Owner |
– – • |
2018-03-22 |
4 |
B |
$1.90 |
$1,655,669 |
D/D |
869,574 |
73,113,418 |
2.45 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
10% Owner |
– – • |
2018-03-23 |
4 |
B |
$1.95 |
$572,358 |
D/D |
294,090 |
73,407,508 |
2.45 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
10% Owner |
– – • |
2018-03-26 |
4 |
B |
$1.90 |
$1,087,553 |
D/D |
571,164 |
73,978,672 |
2.45 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
10% Owner |
– – • |
2018-03-27 |
4 |
B |
$1.92 |
$11,500,200 |
D/D |
6,000,000 |
79,978,672 |
2.45 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
10% Owner |
– – • |
2018-09-07 |
4 |
B |
$1.67 |
$5,000,100 |
D/D |
3,000,000 |
82,978,668 |
2.45 |
- |
|
| APPN |
Appian Corp |
10% Owner |
– – • |
2017-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,820,516 |
2,820,516 |
0 |
- |
|
| APPN |
Appian Corp |
10% Owner |
– – • |
2017-11-20 |
4 |
S |
$19.49 |
$54,971,857 |
D/D |
(2,820,516) |
0 |
0 |
- |
|
| APPN |
Appian Corp |
10% Owner |
– – • |
2017-11-27 |
4 |
S |
$19.49 |
$11,101,894 |
D/D |
(569,620) |
0 |
0 |
- |
|
| APPN |
Appian Corp |
10% Owner |
– – • |
2017-11-27 |
4 |
A |
$0.00 |
$0 |
D/D |
569,620 |
569,620 |
0 |
- |
|
| APPN |
Appian Corp |
10% Owner |
– – • |
2018-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
27,242 |
27,242 |
0 |
- |
|
| APPN |
Appian Corp |
10% Owner |
– – • |
2018-02-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,724,202) |
0 |
0 |
- |
|
| APPN |
Appian Corp |
10% Owner |
– – • |
2018-02-13 |
4 |
A |
$0.00 |
$0 |
I/I |
2,724,202 |
2,724,202 |
0 |
- |
|
| APPN |
Appian Corp |
10% Owner |
– – • |
2018-02-13 |
4 |
D |
$0.00 |
$0 |
D/D |
(27,242) |
0 |
0 |
- |
|
| AVTX |
Avalo Therapeutics, Inc |
10% Owner |
– – • |
2015-10-20 |
4 |
A |
$0.00 |
$0 |
D/D |
594,245 |
594,245 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
– – • |
2021-12-09 |
4 |
S |
$2.95 |
$16,693 |
D/D |
(5,666) |
4,008,329 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
– – • |
2021-12-10 |
4 |
S |
$2.83 |
$24,541 |
D/D |
(8,667) |
3,999,662 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
– – • |
2021-12-13 |
4 |
S |
$2.83 |
$49,558 |
D/D |
(17,501) |
3,982,161 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
– – • |
2021-12-14 |
4 |
S |
$2.56 |
$38,643 |
D/D |
(15,093) |
3,967,068 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
– – • |
2021-12-15 |
4 |
S |
$2.28 |
$65,685 |
D/D |
(28,817) |
3,938,251 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
– – • |
2021-12-16 |
4 |
S |
$2.23 |
$100,546 |
D/D |
(44,993) |
3,893,258 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
– – • |
2021-12-20 |
4 |
S |
$2.21 |
$192,604 |
D/D |
(85,123) |
3,808,135 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
– – • |
2021-12-21 |
4 |
S |
$2.32 |
$95,804 |
D/D |
(41,222) |
3,766,913 |
0 |
- |
|
42 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
